Since the advent of 123 I-meta-iodobenzylguanidine（MIBG）in 1990s, it has been widely used in clinical practice in Japan. Based on the wide range of clinical applications, 123 I MIBG is now incorporated in Japanese Circulation Society s guidelines of nuclear cardiology. The major role of 123 I MIBG has been in determination of severity and prognostic evaluation of heart failure. In addition, assessment of the treatment by various types of medications has been the second major role of 123 I MIBG imaging.
The broad clinical approval of 123 I MIBG in Japan, encompassing cardiac diseases as a whole, has encouraged its use in a wide variety of cardiac conditions. The applications have included assessment of denervated but viable myocardium after acute myocardial infarction, primary and secondary cardiomyopathies, and serious arrhythmic diseases, in addition to the most widely used indication for chronic heart failure（CHF） （1） . New indications of Lewy-body diseases in neurology field were added in the late 1990s.
Prognostic use of 123 I MIBG in heart failure
The primary indication listed in the JCS clinical practice guidelines is assessment of severity of heart failure and prognosis for patients with heart failure （Class I: conditions for which there is evidence or general agreement that a given test is useful and effective） . Concerning the utility of prognostic evaluation, the studies have unanimously concluded that low values of the heart-to-mediastinum ratio（HMR） , a simple average count ratio of cardiac and mediastinal Annals of Nuclear Cardiology Vol. 123 I MIBG late HMR was 1.6, and LVEF was 19%. The estimated event risk was high; 44% for 5 years（13） . In this patient, CRT-D device was implanted and experienced an episode of ventricular tachycardia after MIBG study. Lower panel: a 33-year old woman with DCM in NYHA class II. Her LVEF was 23%, and 123 I MIBG late HMR was calculated to be 2.7. The estimated event risk was 1% for 5 years, indicating good prognosis.
the estimated mortality rate. Future prospective cohort studies will hopefully confirm the validity of this hypothesis.
In the current era of multimodality imaging, echocardiography, cardiac X-ray computed tomography, and 
